BioEntrepreneurship Summit 2019Oct 15-16, 2019
Dr Christoph Massner is an Analyst in the Earlybird Venture Capital Health Fund. He works on deal sourcing, due diligence and deal closing in the sectors of digital health, medical devices, diagnostics, R&D platform technologies, and biopharma. Currently, he serves as a board observer of the Munich-based digital health company wellabe. Christoph told a PhD in Synthetic Biology from the Technical University of Munich.
Investment Manager at Occident Group.Studied Pharmaceutical Sciences and Economics at ETH Zurich.Several years of experience in private equity and venture capital.Responsible for sourcing, due diligence and management of life sciences investments at Occident Group.
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments.
Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler for innovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and hightech sectors with the potential to decisively improve people's lives. We offer Family equity with an entrepreneurial understanding at first hand and technological expertise in the investment team to meet the startups at eye level.
Alexandra is a founding member and partner at Apollo Ventures, a biotech company builder and investment fund focused on developing interventions, that improve human health and longevity. At Apollo, Alexandra is leading the venture creation programs that aim at founding new biotech startups targeting the aging process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical stage biotech companies.
Before joining Apollo Ventures, Alexandra worked with The Boston Consulting Group where she specialized in biopharma strategy, market assessment and asset diligence. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology.
Prof Dr Chase Beisel leads the RNA Synthetic Biology group at the Helmholtz Institute for RNA-based Infection Research (HIRI), a partnership between the Helmholtz Center for Infection Research and the University of Würzburg. Dr. Beisel was a faculty member in the Department of Chemical and Biomolecular Engineering at North Carolina State University prior to joining HIRI in 2018. As part of HIRI, the Beisel group seeks to understand and harness CRISPR-Cas systems to advance the study, diagnosis, and treatment of human disease. Aside from leading his research group, Dr. Beisel co-founded a start-up company (Locus Biosciences) to commercialize CRISPR-based antimicrobials and serves on the scientific advisory board of the AgBiotech company Benson Hill Biosystems.
coming soon ...
Dr Daniel Hansen is the CEO and Cofounder of baccuico, a startup using AI, directed evolution, and synthetic biology to screen for novel antibiotics. Daniel received his bachelor from the University of Oxford and holds masters in both finance (IE Business School) and biotechnology (Imperial College London) and has a PhD in drug discovery from Imperial College London. Before deciding to found baccuico, Daniel worked as an investment banker for Barclays Investment Bank and also completed a short stint in VC at the UCL Tech Transfer Fund. Daniel’s main aim is to solve the antibiotic crisis – something he and his cofounders believe baccuico can achieve by 2025.
Daniela Couto is a Principal at BGV and serves on the boards of CatalYm and Fortico Biotech and is an observer on the board of Mironid. Daniela joined the fund in 2015.
Daniela served as the Managing Director of BGV’s portfolio company Staten Biotechnology from 2015 to 2018 and led the early discussions with Novo Nordisk that resulted in a collaboration agreement. Previously, Daniela served as CEO at Cell2B, a cell therapy company that she co-founded with IP and technology from the group of Prof. Sangeeta Bhatia at the Broad Institute, MIT, dedicated to treat immune and inflammatory diseases.
Daniela holds an MSc degree in Biomedical Engineering and a PhD degree in BioEngineering from Instituto Superior Técnico (IST-UTL) and the Massachusetts Institute of Technology (MIT-Portugal Program).
coming soon ...
Gordon Euller is a Digital Health Partner at APEX Ventures, a european Venture Capital fund. Prior to joining APEX in 2019 Gordon worked as board-certified Radiologist at Medical University Vienna (AKH Wien) where he also graduated from medical school. Before starting his medical career he founded two companies in Eastern Europe, one of them focusing on the recruitment of nurses providing domestic care for elderly patients. As a management consultant with McKinsey&Company in London Gordon developed and implemented various digital and strategy transformations for his healthcare clients (payors/providers, pharma, med-tech). Gordon was also a project manager for the set-up of a private hospital in Abu Dhabi.
German Accelerator Life Science
Marc Filerman is CEO of German Accelerator Life Sciences, an organization enabling US market access and growth for German startups and smaller companies. He co-founded a molecular imaging startup, was Chief Commercial Officer of an NIH-funded homecare technology venture, and has been a consultant since 2013 providing strategy, commercialization and investment guidance to startups. Prior to 2013, Marc held leadership positions in multiple large and smaller healthcare companies, including VP of Global Marketing at iCAD, an AI/ML-based image analysis software company, and Group Director of Marketing for Smith & Nephew’s operating room integration business. Marc has a bachelors and masters degree from MIT in Mechanical Engineering, and started his career designing ultrasound imaging systems.
Miriam Haerst graduated in Mechanical Engineering at the Technical University of Munich and holds a doctorate in Mechanical Engineering. During her doctorate and scientific work, she focused on the processing of plastics for medical applications and the effects of a medical environment on plastics. In 2017, she co-founded the Kumovis GmbH, which develops 3D printers for processing high-performance plastics for regulated markets such as medical technology. The company focuses on the processing of high-performance plastics such as PEEK, which is already established in medical technology. With the innovative technology of Kumovis a reproducible production by means of additive manufacturing is realized. For example, patient-specific implants can be manufactured.
Hans Maria Heyn is Co-Founder and one of the Managing Directors of Smart4Diagnostics GmbH. The Munich based start-up in the field of digital diagnostics changes preanalytics from a trust to an evidence based system. He holds a PhD from Freie Universität Berlin, an MBA of the Berlin School of Economics and an M. Sc. from Krems University. Prior to founding DX-Labtrack he worked as IVD- and MD-regulatory affairs expert and headed the strategy development of a leading European think tank.
Andreas Huber is Scientific Director Life Science and Senior Investment Manager at Bayern Kapital. His background is in biology which he studied at the Technical (TUM) and the Ludwig Maximilians University (LMU) in Munich. Additionally, he obtained a degree in Business Administration and Economics. Prior to Bayern Kapital he worked as an Analyst for a Munich-based Venture Capital company and as Business Development Manager with a Medtech-Software-Start-up.
Bayern Kapital is a Venture Capital company, founded in 1995 by the Bavarian government and invests- always together with other investors- in young, innovative high-tech companies in Bavaria. Since 1995 Bayern Kapital has invested over 300m EUR in more than 270 companies, with a focus on Life Science and IT/Internet Start-ups. Bayern Kapital currently has 325m EUR under management and received funding of almost 200m EUR including the Growth Fund (“Wachstumsfonds”).
Roche Startup Creasphere
Dr Christian Korz is a biochemist and obtained his PhD at the German Cancer Research Center in Heidelberg. He joined Roche Diagnostics in 2003 and held various positions in the Direct Procurement organization before he was appointed Head of Global Brand Management and International Marketing Leader for Roche Applied Science. Christian was responsible for European Pharma Alliances before in 2019 he joined the management team of the first Digital Health Accelerator in Munich – Startup Creasphere.
High Tech Gründerfonds
Infinity Institute Berlin
As an international TEDx speaker coach & storytelling expert Patrick Liebl’s mission is to facilitate impactful presentations, speeches and storytelling that resonate with the audience. He supports speakers, start-ups, institutions and companies to spread their ideas, inspire the audience, get fundings and to bring about change. His coaching, workshops and trainings focus on the three key elements content, authenticity and resonance. Because persuasive content that is shared in an authentic way and resonates with the audience is the prerequisite for every convincing, motivating or inspiring talk.
You can connect with Patrick on linkedIn or at firstname.lastname@example.org
Johanneke has a decade of experience in strategic and operational health care consulting and health economics, including as Senior Manager at KPMG Plexus in London and the Netherlands as well as at Medtronic. She is interested in accelerating the role of technology and innovation in improving health and the health care landscape. At NLC, in her role as Venture Development Manager, she carries main responsibility for a smooth venture building process and personal development of the people within.
Marianne joined Wellington Partners in 2018 as a Principal in the Life Science Team. She currently serves as a board member for Confo Therapeutics.
Marianne obtained a Bachelor’s and Master’s degree with distinction in Biotechnology from the RWTH Aachen University, Germany, and The Scripps Research Institute, San Diego, USA, and conducted her PhD research in the field of Molecular Imaging at the Helmholtz-Institute for Biomedical Engineering, University Hospital Aachen, Germany. The thesis resulted in several publications in prestigious journals and was recognized by the German Society of Biomedical Engineering with the VDE PhD Award.
Prior to joining Wellington, Marianne was an Investment Manager in the Life Science Team of High-Tech Gründerfonds (HTGF), Bonn. In this role she managed a portfolio of seven companies and concluded the initial investments in Cardior Pharmaceuticals and Verovaccines. She represented the fund on the Boards of preOmics and coramaze technologies. Prior to HTGF, Marianne worked as a management consultant and supported pharmaceutical and medtech companies relative to strategy, portfolio and business unit development.
Before co-founding Mecuris as CEO, Manuel Opitz studied industrial & bioengineering at RWTH Aachen and Trinity College Dublin (MSc). After first experiences in innovation and operations management in Germany, China and Switzerland, he finished postgraduate studies in economics at the trinational CDI in Paris (MBA). Afterwards, he focused on medical technologies as a patent broker and startup consultant. In today’s role as CEO of Mecuris, he analyses orthopaedic production processes and uses digital tailoring and additive manufacturing to unlock automation potential for doctors, technicians and patients. As a regular speaker at healthcare, 3D printing & startup conferences, he aims to bridge the gap between digital manufacturing and medical technology.
TVM Capital Life Science
Daniel joined TVM Capital Life Science in Munich in 2016 as Executive-in-Residence. He is responsible for deal sourcing, deal monitoring as well as transaction advisory and currently serves on the Board of a number of portfolio companies.
Prior to TVM, he spent 12 years at Novartis AG holding various Global line functions roles from Research to Sales in three Divisions including Global Franchise Head Strategic Marketing for Immunology & Infectious Diseases with Pharma in Basel, Switzerland, Global Head of Development, Diagnostics with Vaccines & Diagnostics in Emeryville, CA, USA and with Sandoz in Holzkirchen, Germany.
He oversaw and was a team member for multiple collaborations, licensing deals and acquisitions from academic to multi-billion dollar transactions, world-wide commercial launches and FDA / EMA / CFDA / ANVISA registrations with respective clinical trials.
Before joining Novartis he was in the Frankfurt office of McKinsey & Company, Inc.
He is an MD from Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA and was a scientific co-worker at the Institute for Occupational, Social and Environmental Medicine at the University of Mainz for several years.
Klinikum rechts der Isar, TUM
Priv.-Doz. Dr med habil. Dominik Pförringer is a specialist for orthopaedics and trauma surgery, has completed the full-time MBA degree at INSEAD in Fontainebleau and Singapore in 2009. He is working as an orthopaedic and trauma surgeon and DRG officer at the Munich university hospital “echts der Isar” and acts as an advisor and consultant in the fields of venture capital and private equity, as well as the development of digital strategies in healthcare. Dr Pförringer is co-chair of the working group Digitalisation of DGOU (Deutsche Gesellschaft für Orthopädie und Unfallchirurgie). Dr. Pförringer also hosts a quarterly startup meetup in Munich as well as an annual conference on digital health.
Dr Pichler holds a PhD in Biochemistry from the Ludwig Maximilian University of Muenchen (Germany) and a Master in "Business and Management" and is responsible for Commercialization & Finances at PreOmics. Dr Pichler has contributed to the establishment of the customer base of PreOmics, which include more than 300 customers worldwide. He successfully led the market launch of PreOmics’ product portfolio and has developed marketing agreements with companies such as Bruker, HSE AG and Diagenode.
Sebastian Pünzeler is Investment Manager at COPARION since 2016 and responsible for Life Science investments and portfolio management. He currently serves as a board member for HepaRegeniX, Fasciotens and Protembis. Sebastian holds a diploma in Biology from the RWTH Aachen University / the LMU Munich and a PhD in Molecular Biology from the IMPRS-LS Munich.
COPARION provides venture capital to accelerate momentum and growth. With our current active fund of EUR 275 million we have the means to do so.
We support entrepreneurial vision with our know-how, but without intervening in daily business operations. Thanks to 25+ years of team experience in venture capital and in building companies, we discern potentials and open up new perspectives. We have the substance, tenacity and creativity required to mutually manage difficult situations successfully.
We only invest with other co-investors. Our focus is on German companies in the start-up and early growth phase. Per company we invest up to EUR 10 million, usually in several financing rounds of EUR 1-5 million each. We are based in Cologne and Berlin.
CEO of CatalYm since 2017. More than 20 years of experience in executive functions in the biotech industry. Prior to joining CatalYm, he was CEO of Kiadis Pharma N.V. as of 2011and restructured the company. He led Kiadis to its IPO on Euronext in 2015 and to submission of the company’s first MAA to EMA for approval of its lead product, ATIR101.
He served in executive roles as CSO and CEO of Cardion AG, CEO of Igeneon AG, COO of NASDAQ-listed Aphton Corporation, CEO of t2cure GmbH and Affectis AG. He also serves as a member of the Supervisory Board of 4SC AG and the Advisory Board of the ALS Investment Fund.
As Chairman apceth GmbH & Co. KG, he led the negotiations on behalf of its shareholders during the acquisition of apceth Biopharma GmbH by Hitachi Chemical in 2019. He studied biochemistry at Tübingen University and did his PhD work at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany.
Dominic is a Partner of Syncona Investment Management Limited. He is a Director on the Board of Anaveon AG, Gyroscope Therapeutics Limited and an Observer on the Board of Freeline Therapeutics Limited. He was closely involved in the foundation and development of these companies, including their operational and strategic set-up. Prior to joining Syncona, he worked for strategy consultancy L.E.K. Consulting. Dominic received his PhD from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom Degree in Biochemistry and his research has been honoured with national and international prizes and published in Cell, Nature and Science.
Dr. Claus Schulte is a Business Developer at Ascenion GmbH. Claus headed several BD and licensing departments in technology transfer and biotech companies.
He also had brief stints as a biotech entrepreneur and continues to enjoy supporting new ventures.
Veronika Schweighart is the Co-Founder and COO of Climedo Health, a German technology company developing a cloud-based platform for high performance clinical validation of medical devices and pharmaceutical products. Among their first clients are Europe’s leading university hospitals such as the Charité in Berlin and the University of Heidelberg. Holding a degree in Business Administration and Technology Management, Veronika is a serial entrepreneur with international work experience in consulting, business development, and strategic marketing.
Dr Fei Tian joined Vesalius Biocapital as an Analyst in 2012 and was promoted to Principal in 2017, and she is responsible for the deal flow management and due diligence process for the investments. She holds an M.D. (Medical Doctor) degree (2008) from Shanghai Tongji University, People's Republic of China. Fei began her career as a physician in emergency medicine and pursued her interest in pulmonary oncology research for her scientific doctoral degree for a PhD at the Ludwig-Maximilian University and Thoracic Oncology Center, Munich, Germany.
Joachim Vogt is Director Search & Evaluation Western Europe at AbbVie. He is responsible for the identification of European business opportunities across all indications and technologies of interest for AbbVie and serves as key contact for European partners, including academic institutions, biotech companies, venture capital, governments and non-profit organizations.
Joachim spent more than 15 years in the pharmaceutical and biotech industry in BD and research roles. He gained broad experience in- and outlicensing of preclinical and clinical projects as well as research technologies. Before joining AbbVie, Joachim was Director of Early Stage Partnering at Roche, served as Senior Manager at Wilex AG and was Head of IP Licensing at the tech transfer office Bayerische Patentallianz. Joachim holds a diploma in chemistry and received his PhD in protein crystallography at the University of Freiburg.
Moritz Philipp Weisbrodt is the co-founder and CMO of KaiaHealth. During his business and management studies at WHU - Otto Beisheim School of Management (Vallendar) and ESSEC Business School (Paris) he was able to gain first practical experiences in various industries. Before Kaia Health and together with his two co-founders Konstantin Mehl and Manuel Thurner he scaled the premium food delivery company Foodora up to 14 countries back in 2015. In his leisure time, Moritz is into various types of sports as well as into discussing new entrepreneurial ideas.
A Professor for Pharmacology, Heike gained her PhD in neuroendocrinology from the University of Heidelberg. She is Director and Lead External Ecosystem R&D with Sanofi in Germany. Within this role, she is responsible for interactions with academia, biotechs and governmental research organizations for the German Hub. She is responsible for the making of large academic and biotech partnerships (Sanofi’s Open Targets partnership (GSK, EMBL-EBI, Sanger, Takeda, Biogen), the deal with BioNTech and the deal with Evotec/Apeiron. She serves as jury member at international business plan competitions (i.e European Health Catapult) and as investment advisory board member of an investment company. She is associate Professor (apl.) at the Medical faculty (Pharmacology) of Ulm. As of 2010, Heike was Director of Business Opportunities in Aging and Oncology (from evaluation of innovative opportunities to leading due diligences). In 2008, she became member elect of the board of the German Society for Experimental & Clinical Pharmacology and Toxicology. In 2001, she had joined Sanofi-Aventis as Section Head Cell Biology in Thrombosis & Osteoarthritis. Heike Wieland began her career in 1992 with Boehringer Ingelheim Pharma..
Jörg Wischhusen studied biochemistry in Tübingen. After his thesis on immune escape in malignant glioma (supervised by M. Weller and H.G. Rammensee) he became a junior group leader at the University of Würzburg. In 2013 he was appointed professor for Experimental Tumor Immunology. His group explores whether mechanisms that protect embryos from the maternal immune system represent new targets for cancer immunotherapy. This has resulted in the spinoff of a VC-funded biotech company. He is also co-inventor of a platform technology for antigen-specific immunosuppressive therapeutics. This pre-seed project is currently supported by an m4 Award. He authored >80 peer-reviewed publications, is key inventor on 6 patent families, advisor to biotech and pharma companies and an active concert pianist.
Copyright © 2017 BioM Biotech Cluster Development GmbHAlle Rechte vorbehalten